Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Myriad Genetics, |
RCV002307258 | SCV002604729 | likely pathogenic | Ellis-van Creveld syndrome | 2021-12-10 | criteria provided, single submitter | clinical testing | NM_147127.4(EVC2):c.2856_2857delAG(R952Sfs*51) is expected to be pathogenic in the context of EVC2-related Ellis-van Creveld syndrome. This variant is predicted to lead to an abnormal or absent protein product due to the creation of a premature termination codon in EVC2, a gene where loss-of-function variants are known to be pathogenic. Please note: this variant was assessed in the context of healthy population screening. |
Labcorp Genetics |
RCV003099161 | SCV003253201 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2021-12-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with EVC2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg952Serfs*51) in the EVC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC2 are known to be pathogenic (PMID: 17024374, 19810119, 19876929). |